Answers are grounded in this paper and cite their sources.
Investigates low-dose heparin's effectiveness in severe sepsis, indicating potential patient benefits.
signed, and selection bias is therefore possible (i.e., heparin might have been withheld from patients at higher risk for bleeding and also for death).However, we consider this explanation unlikely, since both trials administered experimental anticoagulants and excluded patients at high risk for bleeding.We estimate that the number needed to treat with heparin to prevent one death is 11, but this effect size is also uncertain, because the heparin dosage was not controlled.Treatment with activated protein C represents an important advance in the care of selected patients with sepsis.Further study of low-dose heparin and related agents in such patients is warranted.
No takes yet. Share an insight, caveat, or question.
Davidson et al. (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: